2009 Pharmaceutical Report Card

With people in the U.S. with AIDS expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative new long-term treatment options that offer improved efficacy, safety and tolerability.

The ATAC Pharmaceutical Company HIV/AIDS Report Card evaluates the nine largest HIV/AIDS drug-producing pharmaceutical companies in five categories: drug development portfolio and plans, access to drugs, pricing, community relations and marketing practices. The average final grade was a C-. See below for how ATAC ranked each of the companies on the five categories, and view the additional resources for more information.

ATACreportcard

For more information about the above pharmaceutical companies, please see their individual report cards:

For the complete findings, download the Full ATAC Pharmaceutical Company Report Card on all nine companies here.

Additional Resources

HIV Cure Workshop 2012
ATAC / EATG / GSK joint press release on GSK protocol modifications
Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation
AIDS Treatment Activists Milestones